News

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

More patients who retransitioned to originator infliximab after switching to a biosimilar discontinued infliximab than patients who remained on the biosimilar.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.

This segment of Dr. Kim’s interview featured a discussion on the potential advantages and disadvantages of the new ARS-1 epinephrine nasal spray being considered by the FDA.

For DME eyes that did not sufficiently respond to prior treatment, the intravitreal implant was associated with improvements in both visual and anatomic outcomes.

The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.

Most patients continued treatment with the adalimumab biosimilar over 2 years, with a treatment retention rate of 73.1%.

Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.

Increased physical activity and diet quality were associated with a lower risk of all-cause and cardiovascular disease-related mortality among patients with NAFLD.

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

In their latest recommendation statement, the USPSTF recommends blood pressure screening for all pregnant individuals to detect hypertensive disorders.

These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.

The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a breakdown of the latest news in diabetes management, including FDA clearance of a new insulin pump and a major acquisition within the diabetes world.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.

Jordan Baeker Bispo, PhD, MPH, discusses the importance of colorectal cancer screening, why clinician screening recommendations are so important, and how patient-clinician communication gaps should be addressed.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

A study reveals a link between low free thyroxine and fatty liver risk in type 2 diabetes patients, suggesting a gender-specific thyroid-liver interaction.

The association between antibiotic exposure and increased odds of AMD persisted after adjustment for well-established risk factors for the disease.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

Ahmad Masri, MD, MS, provides his perspective on the APOLLO-B data and reacts to the FDA CRDAC 9 to 3 vote in favor of the benefit-risk profile for patisiran in ATTR-CM.

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.